Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor- positive metastatic breast cancer: A southwest oncology group phase III trial

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2494-2501

  Russell, Christy A ^a   Green, Stephanie J ^a   O'Sullivan, Janet ^a   Hynes, Harry E ^a   Budd, G Thomas ^a   Congdon, James E ^a   Martino, Silvana ^a   Osborne, C Kent ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ESTROGEN RECEPTOR; HYDROCORTISONE; MEGESTROL ACETATE; TAMOXIFEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TREATMENT FAILURE; VOMITING;

EID: 0030845035     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2494     Document Type: Article

References (41)

1. Santen RJ, Worgul TJ, Samojlik E, et al: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305:545-551, 1981
2. Smith IE, Harris AL, Morgan M, et al: Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast cancer. Cancer Res 42:3430-3433, 1982 (suppl)
3. Harvey HA, Lipton A, White DS, et al: Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res 42:3451-3453, 1982 (suppl)
4. Smith IE, Harris AL, Morgan M, et al: Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomised cross-over trial. Br Med J 283:1432-1434, 1981
5. Gale KE, Andersen JW, Tormey DC, et al: Hormonal treatment for metastatic breast cancer. An ECOG group phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73:354-361, 1994
6. Sedlacek SM: An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol 15:3-13, 1988 (suppl 1)
7. Lundgren S: Progestins in breast cancer treatment. Acta Oncol 31:709-722, 1992
8. Robertson JFR, Williams MR, Todd J, et al: Factors predicting the response of patients with advanced breast cancer in endocrine (Megace) therapy. Eur J Cancer Clin Oncol 25:469-475, 1989
9. Kimmick G, Muss HB: Current status of endocrine therapy for metastatic breast cancer. Oncology 9:877-894, 1995
10. Samonis G, Margioris AN, Bafaloukos D, et al: Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG + MPA in generalized breast cancer. Oncology 51:411-415, 1994
11. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemoth Rep 50:163-170, 1966
14. Cox DR: Regression models and life tables. J R Stat Soc (B) 34:187-202, 1972
15. Cox DR: The Analysis of Binary Data. London, United Kingdom, Methuen, 1970
16. Muss HB: Endocrine therapy for advanced breast cancer: A review. Br Cancer Res Treat 21:15-26, 1992
17. Pritchard KI, Sutherland DJA: The use of endocrine therapy. Hematol Oncol Clin North Am 3:765-805, 1989
18. Ingle JN, Green SJ, Ahmann DL, et al: Progress report on two clinical trials in women with advanced breast cancer. Trial I: Tamoxifen versus tamoxifen plus aminoglutethimide; Trial II: Aminoglutethimide in patients with prior tamoxifen exposure. Cancer Res 42:3461-3467, 1982 (suppl)
19. Crawford DJ, George WD, Smith DC, et al: Cyclic sequential endocrine therapy for advanced breast cancer using a combination of tamoxifen and megestrol acetate. Oncology 51:13-18, 1994 (suppl 1)
20. Gill PG, Vebski V, Snyder R, et al: Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival inpatients with metastatic breast cancer. Ann Oncol 4:741-744, 1993
21. Morgan LR: Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal women. Semin Oncol 12:43-47, 1985 (suppl 1)
22. Kaye SB, Woods RL, Fox RM, et al: Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. Cancer Res 42:3445-3447, 1982 (suppl)
23. Buzdar AU, Powell KC. Blumenschein GR: Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M.D. Anderson Hospital experience. Cancer Res 42:3448-3450, 1982 (suppl)
24. Paterson AHG, Hanson J, Pritchard KI, et al: Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin Oncol 17:52-62, 1990 (suppl 9)
25. Muss HB, Wells HB, Paschold EH, et al: Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - A phase III trial of the Piedmont Oncology Association. J Clin Oncol 6:1098-1106, 1988
26. Ross MB, Buzdar AU. Blumenschein GR: Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer 49:413-417, 1982
27. Ingle JN, Ahmann DL, Green SJ, et al: Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 5:155-160, 1982
28. Nemoto T, Rosner D, Patel JK, et al: Aminoglutethimide in patients with metastatic breast cancer. Cancer 63:1673-1675, 1989
29. Parazzini F, Colli E, Scatigna M, et al: Treatment with tamoxifen and progestin for metastatic breast cancer in postmenopausal women: A quantitative review of published randomized clinical trials. Oncology 50:483-489, 1993
30. Brufman G, Isacson R, Haim N, et al: Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide. Oncology 51:258-261, 1994
31. Espie M: Megestrol acetate in advanced breast carcinoma. Oncology 51:8-12, 1994 (suppl)
32. Nagel GA, Wander HE, Blossey HC: Phase II study of aminoglutethimide and medroxyprogesterone acetate, in the treatment of patients with advanced breast cancer. Cancer Res 42:3442-3444, 1982 (suppl)
33. Garcia-Giralt E, Ayme Y, Carton M, et al: Second and third line hormonotherapy in advanced post-menopausal breast cancer: A multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat 24:139-145, 1992
34. Lundgren S, Gundersen S, Klepp R, et al: Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat 14:201-206, 1989
35. Canney PA, Priestman TJ, Griffiths T, et al: Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. J Natl Cancer Inst 80:1147-1151, 1988
36. Horton J, Knuiman M, Keller AM, et al: Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. Cancer 60:2137-2140, 1987
37. Schacter LP, Rozencweig M, Canetta R, et al: Overview of hormonal therapy in advanced breast cancer. Semin Oncol 17:38-46, 1990 (suppl 9)
38. Stuart-Harris R, Dowsett M, Bozek T, et al: Low-dose aminoglutethimide in treatment of advanced breast carcinoma. Lancet 2:604-606, 1984
39. Dowsett M, Santner SF, Santen RJ, et al: Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. Br J Cancer 52:31-35, 1985
40. Buzdar A, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J Clin Oncol 14:2000-2011, 1996
41. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995